The definition of BRPC has expanded to include everything from minimal venous involvement to 180 degree abutment of the SMA.  It is important to determine if there is arterial involvement.  If there is, the best data show that XRT helps with R0 resections. In our experience at MDACC, ...

It is true that 54Gy of XRT did not improve OS in locally advanced patients in the LAP-07 trial, but that study is not relevant to the BRPC population with arterial involvement (also T4 but resectable) where the issue is improving margin negative resectability.  Margins are +80% of the time wit...

I would add the findings of Hammel et al. published in JAMA recently: patients with stage III locally advanced disease (so T4, unresectable at diagnosis) were randomized to chemo (gemcitibine, since the trial was started before FOLFIRINOX and Abraxane) vs. chemoRT (after an earlier randomization to ...